Skip to main content

Home/ Dr. Goodyear/ Group items tagged human papillomavirus

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Human papillomavirus and Epstein Barr virus in prostate cancer: Koilocytes indicate pot... - 0 views

onlinelibrary.wiley.com/...pros.22562

cancer virus prostate cancer EBV HPV Epstein-Barr virus human papilloma virus

shared by Nathan Goodyear on 03 Oct 18 - No Cached
  • Nathan Goodyear on 03 Oct 18
     
    Is prostate cancer the result of viral infection.  Study suggests HPV and EBV play a role.
Nathan Goodyear

Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vacc... - 0 views

jid.oxfordjournals.org/...385.long

HPV gardasil vaccine vaccinations vaccines

shared by Nathan Goodyear on 11 May 16 - No Cached
  • Nathan Goodyear on 11 May 16
     
    study points to the lower HPV rats with the advent of the HPV vaccine; yet the greatest reduction in  HPV prevalence was in unvaccinated girls.
Nathan Goodyear

Human papillomavirus vaccine and systemic lup... [Clin Rheumatol. 2013] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...23624585

HPV vaccine vaccination Lupus autoimmune disease.

shared by Nathan Goodyear on 11 Nov 13 - No Cached
  • Nathan Goodyear on 11 Nov 13
     
    6 cases presented in women that developed Lupus following HPV vaccination.
Nathan Goodyear

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multi... - 0 views

www.ncbi.nlm.nih.gov/...PMC5809128

cancer anal cancer nivolumab immunotherapy

shared by Nathan Goodyear on 13 Jul 18 - No Cached
  • Patients received a median of six doses of nivolumab
  • four of the first 12 patients had partial responses
  • Nine (24% [95% CI 15–33]) of 37 patients achieved a response (seven partial responses and two complete responses
  • ...16 more annotations...
  • no treatment-related deaths
  • the most common adverse events were anaemia (26 [70%]), fatigue (25 [68%]), and rash
  • hypothyroidism
  • hypothyroidism
  • nivolumab-related autoimmune hypothyroidism, which resolved after a short course of corticosteroids
  • No grade 3 or 4 adverse events occurred
  • Nivolumab resulted in objective responses in 24% of patients with metastatic SCCA
  • Historically, doublet chemotherapy with cisplatin and fluorouracil has been the most common treatment for patients with metastatic SCCA
  • our results suggest that immune checkpoint blockade agents might extend overall survival beyond currently available therapies, especially if provided early in the disease treatment course
  • the dose of nivolumab we used differs from the 2016 recommendation of a fixed 240 mg every 2 weeks
  • 25% of patients develop distant metastases
  • most patients with localised SCCA are cured by chemoradiation
  • More than 90% of cases of SCCA are linked to prior infection with human papillomavirus (HPV)
  • Within tumour cells, HPV oncoproteins are immunogenic and can trigger an anti-tumour host immune response by recruitment of tumour-infiltrating lymphocytes
  • Tumour cells express PD-L1 and, on binding its inhibitory receptor PD-1 on the surface of T cells, downregulate T-cell activation and thwart the local anti-tumour immune response
  • Nivolumab is a humanised monoclonal antibody against PD-1 that disrupts this interaction, enabling T-cell cytotoxicity. It has activity as a monotherapy in advanced solid cancers, such as head and neck cancer, melanoma, non-small-cell lung cancer, and renal cell carcinoma
  • Nathan Goodyear on 13 Jul 18
     
    study finds nivolumab helpful in some patients with surgically unresectable or metastatic anal cancer.  The dose used was 3 mg/kg every 2 weeks. 
1 - 5 of 5
Showing 20▼ items per page